In silico Identification of Potential Hepatitis B Virus HBx Inhibitors Through Molecular Docking Analysis
Maryam Aliza , Bibi Haleema
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (3) : 20 -31.
Hepatitis B virus (HBV) remains a major contributor to chronic liver disease worldwide and represents a significant global health challenge. The HBx protein plays an important role in HBV replication and viral pathogenesis and is therefore considered a promising therapeutic target. In the present study, an in silico molecular docking approach was employed to identify potential HBx inhibitors from a selected group of fourteen compounds. The three-dimensional structure of the HBx protein was predicted using the I-TASSER server, and the selected compounds were subjected to molecular docking using PyRx and AutoDock Vina. The docking results revealed that several compounds exhibited favorable predicted binding affinities toward HBx, with SC75741 showing the most favorable docking score (−9.8 kcal/mol), followed by Rutin (−9.1 kcal/mol), Cynarin (−8.6 kcal/mol), and Ledipasvir (−8.4 kcal/mol). Notably, Cynarin, which is not currently an approved anti-HBV drug, demonstrated a favorable docking score and interactions with several important HBx residues, highlighting its potential as a candidate lead compound for further investigation. Overall, the findings suggest that the identified compounds, particularly SC75741, Rutin, Cynarin, and Ledipasvir, may serve as potential candidates for HBx-targeted anti-HBV drug discovery.
Hepatitis / Bioinformatics / HBV / HBx / Computational Drug Design
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
/
| 〈 |
|
〉 |